摘要
目的通过对消化性溃疡患者实施不同的治疗方案,观察两组患者治疗后的临床效果,分析和探讨不同治疗方案的临床特征。方法从2015年1月-2017年12月到该院诊治的消化性溃疡患者中随机抽取76例,通过随机数字法将76例患者随机分为对照组38例:实施法莫替丁片+阿莫西林+克拉霉素治疗,观察组实施奥美拉唑肠溶片+阿莫西林+克拉霉素治疗,观察两组患者治疗效果、Hp清除率以及不良反应发生率。结果观察组患者治疗有效率为92.11%,高于对照组,差异有统计学意义(χ^2=13.285,P<0.05);观察组患者Hp清除率为94.74%,高于对照组,差异有统计学意义(χ^2=16.984,P<0.05),复发率为2.63%低于对照组(χ^2=10.236,P<0.05);观察组患者不良反应发生率为5.26%,低于对照组,差异有统计学意义(χ^2=11.089,P<0.05)。结论奥美拉唑肠溶片+阿莫西林+克拉霉素治疗方案可以提高消化性溃疡患者的治疗效果,Hp清除率提高,减少不良反应事件的发生,有效降低患者病痛,提高生活质量,降低治疗后复发率,是一项值得临床推广应用的临床治疗方案。
Objective To observe the clinical effects of two groups of patients after treatment by different treatments for patients with peptic ulcer, and to analyze and explore the clinical features of different treatment options. Methods From January 2015 to December 2017, 76 patients were randomly selected from the patients with peptic ulcer. The randomized digital method was used to randomly divide 76 patients into 38 patients in the control group: famotidine tablets +amoxicillin + clarithromycin treatment, the observation group was treated with omeprazole enteric-coated tablets +amoxicillin + clarithromycin, the treatment effect, Hp clearance rate and incidence of adverse reactions were observed.Results The effective rate of the observation group was 92.11% higher than that of the control group,the difference was statistically significant(χ^2=13.285, P<0.05). The Hp clearance rate of the observation group was 94.74% higher than that of the control group,the difference was statistically significant(χ^2=16.984, P<0.05). 2.63% was lower than the control group,the difference was statistically significant(χ^2=10.236, P<0.05). The incidence of adverse reactions in the observation group was 5.26% lower than that in the control group,the difference was statistically significant(χ^2=11.089,P<0.05). Conclusion Omeprazole enteric-coated tablets + amoxicillin + clarithromycin can improve the therapeutic effect of patients with peptic ulcer, improve the clearance rate of Hp, reduce the incidence of adverse reactions, effectively reduce the pain of patients, improve the quality of life, and reduce the recurrence rate after treatment is a clinical treatment plan worthy of clinical application.
作者
周成林
ZHOU Cheng-lin(Department of Gastroenterology,Donghai County People's Hospital,Lianyungang,Jiangsu Province,222300 China)
出处
《系统医学》
2019年第19期55-57,共3页
Systems Medicine
关键词
HP
消化性溃疡
奥美拉唑肠溶片
Hp
Peptic ulcer
Omeprazole enteric-coated tablets
